Predicting Suboptimal Ruxolitinib Response in Myelofibrosis: Lessons To Be Learned from the POIESIS Trial

Supplements and Featured Publications, Integrating MDM2 Inhibition Into Myelofibrosis Management, Volume 1, Issue 1